A Multi-center, Open-label, Single-arm, Phase IV Clinical Trial to Evaluate the Preference Regarding Convenience of Medication, Efficacy and Safety After Switching to SUGAMET®XR Tablet 5/1000mg in Patients With Type 2 Diabetes and Renal Diseases
Latest Information Update: 06 Dec 2022
At a glance
- Drugs Evogliptin/metformin (Primary)
- Indications Kidney disorders; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Dong-A ST
- 09 Dec 2020 New trial record